LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Vertex Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

438.4 0.96

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

435.74

Max

438.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-267M

646M

Verkoop

-142M

2.8B

K/W

Sectorgemiddelde

30.42

56.602

EPS

4.06

Winstmarge

23.33

Werknemers

6,100

EBITDA

-556M

630M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.94% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-6.9B

113B

Vorige openingsprijs

437.44

Vorige sluitingsprijs

438.4

Nieuwssentiment

By Acuity

44%

56%

143 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2025, 21:00 UTC

Winsten

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

10 feb 2025, 22:11 UTC

Winsten

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 jan 2025, 00:19 UTC

Belangrijke Marktbewegers

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 dec 2024, 12:25 UTC

Belangrijke Marktbewegers

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 nov 2024, 21:44 UTC

Winsten

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

6 mei 2025, 16:31 UTC

Winsten

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 mei 2025, 20:03 UTC

Winsten

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 mei 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 mei 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 mei 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 mei 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 apr 2025, 11:00 UTC

Top Nieuws

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 apr 2025, 09:30 UTC

Top Nieuws

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 21:12 UTC

Winsten

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 feb 2025, 14:21 UTC

Winsten

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 feb 2025, 21:12 UTC

Winsten

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 feb 2025, 21:12 UTC

Winsten

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 feb 2025, 21:11 UTC

Winsten

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 feb 2025, 21:04 UTC

Winsten

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 feb 2025, 21:04 UTC

Winsten

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 feb 2025, 21:02 UTC

Winsten

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 feb 2025, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 feb 2025, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 feb 2025, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 feb 2025, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 jan 2025, 09:59 UTC

Populaire aandelen

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 nov 2024, 22:21 UTC

Winsten

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 nov 2024, 21:25 UTC

Winsten

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 nov 2024, 21:03 UTC

Winsten

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

Peer Vergelijking

Prijswijziging

Vertex Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

16.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 512.95 USD  16.94%

Hoogste 621 USD

Laagste 423 USD

Gebaseerd op 26 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vertex Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

26 ratings

14

Buy

12

Hold

0

Sell

Technische score

By Trading Central

428.545 / 498.65Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

143 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.